• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Provista Diagnostics

edit

Provista Diagnostics, Inc., a Delaware company, develops and commercializes breakthrough, easy to administer blood-based diagnostic tests for early oncology-related disease state recognition and detection purposes. The Company’s focus is on oncology-related diagnostics where a significantly high, unmet clinical need for such testing products exists. Near term development and commercialization efforts focus on women’s cancers such as breast and ovarian cancer.

Provista Diagnostic’s technologies are developed at our CLIA accredited, GLP compliant, 13,610 sq/ft laboratory facility based in Scottsdale, Arizona. Recently, Provista has formed corporate headquarters in New York to take advantage of the sales, marketing, regulatory and financial expertise in the northeast US.

Recent Milestones

edit

• 
  Provista Diagnostics received $6M in Series A funding. (4/17/13)
  Posted 4/18/13 at 3:53am via dowjones.com
• 
  Provista Diagnostics received $2.5M in Series A funding. (9/18/12)
  Posted 9/18/12 at 8:11pm via dowjones.com
• 
  Provista Diagnostics received $5M in Series A funding. (3/7/12)
  Posted 3/12/12 at 5:16pm via provistadx.com

Videos

Screenshots

edit

Above: Home Page
Uploaded: 3/13/12

Sources

1. Provista Diagnostics Announces the Closing of Series A Preferred Financing (provistadx.com) [edit]
2. Provista Diagnostics Adds $2.5M to Series A for Breast Cancer Test (pevc.dowjones.com) [edit]
3. Provista Diagnostics Closes $6M Series A for Breast-Cancer Test Trials (pevc.dowjones.com) [edit]